Systemic therapy for advanced basal cell carcinoma
Menés respectivement sur 230 et 1 227 patients atteints d'un carcinome basocellulaire de stade avancé, ces deux essais évaluent l'efficacité et la toxicité de deux inhibiteurs de la signalisation Hedghehog, le sonidégib et le vismodégib
Basal cell carcinoma is the most common cancer to affect people with fair skin. Tumours develop as a result of aberrant signalling in the Hedgehog pathway, which is essential to embryonic skin development and wound repair. They usually occur on the head, and in most cases are amenable to treatment with topical therapy, surgery, or radiotherapy. Mohs' surgery involves microscopic examination of the tumour and surrounding skin to improve clearance, and has become the gold standard for certain high-risk facial basal cell carcinoma, including those that have recurred.
The Lancet Oncology , commentaire, 2014